Sector News

AstraZeneca to cut nearly 100 jobs at U.K. site as efficiencies ‘hammer’ workers

March 28, 2019
Life sciences

Less than two years after revealing a multimillion-dollar upgrade plan for its plant in Macclesfield, U.K., AstraZeneca is cutting back, slashing almost 100 jobs in what local union called a “hammer blow” to U.K. manufacturing.

AstraZeneca will let go of 94 employees—out of a total of around 1,800—at the Macclesfield facility in Cheshire, according to GMB Union, which said the cut wouldn’t take place until 2020. The Macclesfield site, which makes medicines such as legacy prostate cancer drug Zoladex, is AZ’s second largest manufacturing facility.

The layoff isn’t necessarily a bad reflection on AZ’s business. It follows a $50 million investment the British drugmaker made there on packaging. Following the upgrade, AZ said its efficiency has increased significantly, and according to GMB, that means fewer employees are needed.

The workers’ union depicted the company’s decision as “a hammer blow for manufacturing in the North West—and the U.K. as a whole,” said GMB Organizer Stephen Boden in a statement.

Like others, AZ has been rethinking its global manufacturing network. Earlier this year, AZ unveiled plans to shutter two plants in Boulder and Longmont, Colorado, and lay off 210 workers stationed there as part of a plan to streamline its biologics supply chain and consolidate the biologics manufacturing network at a large-scale facility in Frederick, Maryland.

AZ also has put investments in U.K. manufacturing on hold as Brexit uncertainty clouds the entire U.K. economic outlook. Last October, AZ Chairman Leif Johansson told France’s Le Monde that the company “will maintain our decision not to invest” if Brexit future remains unclear, according to Reuters.

AZ has two other operations in Cheshire, including the Alderley Park R&D center—whose functions and employees are being moved to the new Cambridge, U.K., campus—and a vaccine research team at Speke, near Liverpool. It’s not clear whether jobs at those sites will be affected, and AZ hasn’t immediately responded to a FiercePharma request for confirmation.

Meanwhile, construction of AZ’s new Cambridge headquarters has suffered repeated delays and has reportedly gone over budget. In its 2018 annual report, the company said it’s expected to start occupation of the building from 2020 rather than have it fully operational in that year as previously reported.

By Angus Liu

Source: Fierce Pharma

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).